What did @rylan.clark actually say?
Rylan walked through reconstituting lyophilized BPC-157 and TB-500 using bacteriostatic water, an insulin syringe, and alcohol prep pads. He recommended 2 mL of BAC water for a 10 mg BPC-157 vial, dosed at "one milligram daily" split into two injections of 10 units each. For TB-500, he went with 1 mL BAC water for a 5 mg vial, at "1 milligram every other day" or 20 units per injection. Throughout, he framed everything as "petri dish usage only" and repeated that none of it is medical advice.
He also called the solvent "bacteria static water" repeatedly, which is just a mispronunciation of bacteriostatic water. Small thing, but worth noting for anyone new to this space who might search the wrong term. He directed viewers to a subreddit for sourcing and suggested using ChatGPT or DeepSeek to work out dosing math, which is, to put it gently, not how you want to be calculating injectable compound doses.
Does the science back this up?
The reconstitution technique itself is largely sound. The underlying science on BPC-157 and TB-500 is more complicated and far less settled than the peptide community tends to admit.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It has shown regenerative and anti-inflammatory effects in rodent models across multiple tissues. Sikiric et al. (2018, Current Pharmaceutical Design) documented healing effects on tendons, ligaments, and gut tissue in animal studies. The problem: virtually all BPC-157 research is preclinical. There are no completed, peer-reviewed human clinical trials establishing safety or efficacy for any indication at any dose.
TB-500, a synthetic fragment of Thymosin Beta-4, has a similarly thin human evidence base. Animal studies suggest roles in tissue repair and angiogenesis (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but human data is essentially nonexistent outside of small ophthalmic trials for a different formulation.
The dosing figures Rylan cites, 1 mg/day for BPC-157 and 1 mg every other day for TB-500, appear to be drawn from anecdotal community consensus, not clinical literature. There is no established human therapeutic dose for either compound.
What did they get wrong (or right)?
Let's give credit where it's due. The core reconstitution technique is correct. Using bacteriostatic water instead of sterile water matters because BAC water contains 0.9% benzyl alcohol, which inhibits bacterial growth and extends shelf life of the reconstituted vial. Drawing air into the vial to equalize pressure before pulling out liquid is standard practice. Injecting slowly along the vial wall to avoid denaturing the peptide is also correct and often skipped in these tutorials.
Recommending refrigeration post-reconstitution is right. Lyophilized peptides are stable at room temperature for months; reconstituted peptides degrade significantly faster and should be kept at 2-8 degrees Celsius.
What he got wrong is more consequential. His dosing math contains an error. He says he uses 2 mL of BAC water for "a 10 milliliter vial of peptides," but peptide vials are measured in milligrams, not milliliters. A standard BPC-157 vial is 5 mg or 10 mg. If you reconstitute 10 mg in 2 mL (2000 mcL), then 10 units on an insulin syringe equals 100 mcL, which delivers 0.5 mg, not 1 mg. His math produces half his stated dose. Pointing people to an AI chatbot to resolve injectable compound math is not a responsible substitute for a compounding pharmacist or a clinician.
The "petri dish" framing is a legal workaround that fools no one. The hashtags are gym and lifting. The dosing is for humans.
What should you actually know?
Peptides like BPC-157 and TB-500 are not FDA-approved for human use. In the United States, they are classified as research chemicals. The FDA issued a guidance in 2023 removing BPC-157 and TB-500 from the list of substances that can be compounded by 503A pharmacies, meaning legitimate compounding pharmacies can no longer legally produce them for human use in most circumstances.
That regulatory shift matters. It means the vials circulating in the fitness community are coming from research chemical suppliers with no obligation to meet pharmaceutical-grade purity or sterility standards. Independent testing by organizations like Janoshik and others has found dosing inconsistencies and contamination in samples from various suppliers.
If you are considering any injectable compound outside of a licensed medical provider's supervision, the risks include infection from non-sterile products, unknown pharmacokinetics, drug interactions that have not been studied, and zero recourse if something goes wrong. "Do your own research" on a subreddit is not a clinical safety net.
- BPC-157 and TB-500 have no approved human dosing guidelines because no human clinical trials have established them.
- The FDA's 2023 guidance restricts compounding of these peptides, meaning unregulated sources are the primary supply channel.
- Reconstituting with bacteriostatic water and refrigerating is technically correct procedure, but correct technique does not make an unvetted compound safe.
- Rylan's dosing math contains an error that would result in half the intended dose based on his own stated reconstitution volume.